Macquarie Group LTD Sarepta Therapeutics, Inc. Transaction History
Macquarie Group LTD
- $86.4 Billion
- Q4 2024
A detailed history of Macquarie Group LTD transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 55,533 shares of SRPT stock, worth $5.9 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
55,533
Previous 38,910
42.72%
Holding current value
$5.9 Million
Previous $4.86 Million
38.96%
% of portfolio
0.01%
Previous 0.01%
Shares
29 transactions
Others Institutions Holding SRPT
# of Institutions
536Shares Held
87.4MCall Options Held
1.55MPut Options Held
1.35M-
Black Rock Inc. New York, NY10.3MShares$1.1 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$966 Million0.02% of portfolio
-
Capital International Investors Los Angeles, CA8.7MShares$924 Million0.21% of portfolio
-
Janus Henderson Group PLC London, X04.33MShares$460 Million0.28% of portfolio
-
State Street Corp Boston, MA4.07MShares$433 Million0.02% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $9.31B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...